Sigyn Therapeutics, Inc.
SIGY
$4.15
$0.153.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.36% | 25.35% | 15.75% | 13.43% | 11.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.61% | 24.84% | 23.44% | 24.51% | 14.35% |
| Operating Income | -2.61% | -24.84% | -23.44% | -24.51% | -14.35% |
| Income Before Tax | 19.43% | -4.30% | -1.45% | 0.83% | -41.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.43% | -4.30% | -1.45% | 0.83% | -41.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.43% | -4.30% | -1.45% | 0.83% | -41.51% |
| EBIT | -2.61% | -24.84% | -23.44% | -24.51% | -14.35% |
| EBITDA | -2.82% | -25.17% | -23.76% | -24.73% | -14.40% |
| EPS Basic | 32.39% | 15.68% | 18.10% | 19.88% | -22.03% |
| Normalized Basic EPS | 39.53% | 13.03% | 15.29% | 7.78% | -37.73% |
| EPS Diluted | 32.16% | 15.57% | 18.39% | 21.87% | -15.54% |
| Normalized Diluted EPS | 39.53% | 13.03% | 15.29% | 7.78% | -37.73% |
| Average Basic Shares Outstanding | 21.13% | 21.82% | 23.05% | 23.87% | 17.65% |
| Average Diluted Shares Outstanding | 21.13% | 21.82% | 23.05% | 23.87% | 17.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |